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the conThe excessive increase of anything causes
a reaction in the opposite direction.—Plato (428 BC–348 BC) (1)SEE PAGE 1361A rterial healing or vascular response afterpercutaneous coronary interventions (PCIs)describes a reparative mechanism to acute
procedural injury attributed to balloon barotrauma
and/or stent deployment itself (2,3). Early vascular
responses after bare metal stent or drug-eluting stent
(DES) placement are driven by ﬁbrin- and platelet-
rich thrombi depositions and migration of smooth
muscle cells. In contrast, late vascular responses to
DES are primarily attributed to delayed strut healing
subsequent to drug toxicity, polymer-induced inﬂam-
mation followed by hypersensitivity reactions, and
in-stent neoatherosclerosis leading to late target
lesion revascularization (TLR) or late stent throm-
bosis. Further technological innovations in the quest
for optimal coronary stenting (4) led to the develop-
ment of bioresorbable scaffolds (BRSs) made of biode-
gradable polymers or biocorrodible metals. The
property of transient vessel scaffolding (w6 months)
and complete resorption over a period of 3 years
with subsequent restoration of vessel anatomy
(form), physiology (function), and local hemody-
namic milieu promises to eliminate or reduce the
risk of late vascular responses (5,6).
Bench work in experimental porcine models after
Absorb Bioresorbable Vascular Scaffold (BVS) (Abbott
Vascular, Santa Clara, California) deployment hasals published in JACC: Cardiovascular Interventions reﬂect the
f the authors and do not necessarily represent the views of JACC:
ascular Interventions or the American College of Cardiology.
he Andreas Gruentzig Cardiovascular Center, Department of
e, Division of Cardiology, Emory University School of Medicine,
Georgia. Dr. Samady has received a research grant from Abbott
r. Dr. Gogas has reported that he has no relationships relevant to
tents of this paper to disclose.indicated using optical coherence tomographic (OCT)
imaging matched with histology that at 2 years the
polymeric struts are being replaced by proteoglycan-
rich matrix (glycoconjugates), which at 3 years is
substituted with connective tissue, and at 4 years by a
layer of homogeneous ﬁbrous neointimal tissue (7,8).
Prospective clinical intravascular imaging studies
investigating the Absorb BVS have shown the
following: 1) in-scaffold late lumen loss comparable to
that observed with metal everolimus-eluting stents at
1, 2, and 3 years; 2) restoration of coronary vasomotor
function at 1 year assessed with intracoronary meth-
ylergonovine or acetyl choline; 3) nonobstructive
neointimal proliferation proximal to the scaffold
(proximal edge vascular response) at 2 years and
edge restenosis of 3% resulting in TLR (edge effect)
comparable to that observed with metal DES; and
4) scaffold area expansion attributed to loss of scaf-
fold integrity at 3 years (9,10).In this issue of JACC: Cardiovascular Interventions,
Zhang et al. (11) report a substudy of the ABSORB
Cohort B trial describing the in-scaffold and edge
vascular responses after implantation of the Absorb
BVS. The ABSORB Cohort B trial (B1 and B2 subgroups)
in which intravascular imaging and clinical assess-
ment at multiple time points was performed (Figure 1)
was the ﬁrst international registry to provide an in
depth evaluation of the second-generation BVS
(Revision 1.1) approved for clinical use in Europe
since 2011. The current longitudinal investigation,
which excludes patients with clinically relevant edge
restenosis (angiographic diameter stenosis >50% at
follow-up), reports truly serial OCT imaging ﬁndings
and demonstrates at 3 years the following: 1) signiﬁ-
cantly greater in-scaffold neointimal responses
compared with edge vascular responses; 2) numeri-
cally greater neointimal proliferation at the proximal
compared with the distal edge, which appears to be
FIGURE 1 The ABSORB Cohort B Trial Design and the IVUS- Versus OCT-Based Edge Demarcation After BRS Implantation
(A) The last frame of the scaffolded segment with IVUS and OCT (longitudinal views are also shown). (B to F) The IVUS-derived edge includes
cross sections with struts (presence of scrambling effect) as opposed to the OCT-derived edge, which sharply demarcates the edge as a
segment with no struts. Reprinted, with permission, from Gogas et al. (10,12). (Green asterisk) Coronary computed tomography was also
performed at 18 months. BRS ¼ bioresorbable scaffold; IVUS ¼ intravascular ultrasound; OCT ¼ optical coherence tomography; PB ¼ pullback.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 2 , 2 0 1 4 Gogas and Samady
D E C E M B E R 2 0 1 4 : 1 3 7 0 – 3 Shedding Light on Scaffold Vascular Response
1371contiguous with the adjacent in-scaffold vascular
response; and 3) numerically lesser neointimal pro-
liferation at the mid-segment of the scaffold
compared with the scaffold edges. This is the ﬁrst
in vivo light-based imaging study to investigate
edge vascular responses after implantation of
BRS technologies. Previous intravascular ultrasound
(IVUS)–based observations have indicated modest
proximal edge constrictive remodeling and slight but
signiﬁcant proximal lumen loss of w7% at 1 and
2 years, respectively (10,12,13). The current OCT-
based study conﬁrms the aforementioned IVUS-
based observations of an edge vascular response
with further considerations at a 3-year time point and
raises 3 provocative mechanistic questions.
First, why should a biodegradable scaffold that is
replaced by proteoglycan-rich matrix at 2 years and
by connective tissue at 3 years result in a persistentedge vascular response at this time point? The
underlying mechanisms leading to early edge and
in-scaffold vascular responses are similar to those
driving early DES responses and likely relate to
the geographic miss (axial or longitudinal) during
scaffold deployment, scaffold design and effect on
vascular curvatures affecting local ﬂuid mechanics
and wall shear stress conditions, underlying plaque
burden and phenotype, as well as biological factors
related to the antiproliferative agent eluted from the
platform (10,14).
Due to scaffold resorption, the factors driving late
vascular responses to the BRS aremore likely driven by
the changing solid biomechanical environment (strut-
wall interaction) and ﬂuid mechanics within the scaf-
fold and over the transition zones. Indeed, changes in
solid mechanical properties at stent edges can induce
zones of increased stress concentration and high stress
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1372gradients inducing neointimal proliferation. BRSs are
designed with an mean strut thickness of 150 mm
(similar to the Cypher stent) to compensate for the
inferior tensile strength and modulus of elasticity
compared with conventional metal DES. This rectan-
gular and thick strut design generates zones of ﬂow
stagnation or recirculation with low wall shear stress
at the sides of the struts generating an initial rapid
vascular response that slows down as soon as resorp-
tion occurs. The edge that is considered a transitional
segment from the supported (scaffold) to an unsup-
ported area (no scaffold) undergoes additional
straightening and is prone to changes in the local solid
and ﬂuid mechanical environment. The rate and
magnitude of strut resorption and restoration of
vascular anatomy are anticipated to deﬁne the extent
of vascular responses as described by Plato: “The
excessive increase of anything causes a reaction in the
opposite direction” (1).
The aforementioned pathogenetic mechanisms
remain to be elucidated in the randomized imaging
substudy of ABSORB III, RESTORATION (Evaluation
and Compa R ison of Three-Dimensional Wall Sh E ar
Stress Pattern S and Neoin T imal Healing F O llowing
Pe R Cutaneous Coron A ry Interven TION with Absorb
Everolimus-Eluting Bioresorbable Vascular Scaffold
Compared to Xience V or Xience Prime Everolimus-
Eluting Metallic Stent) trial, which intends to eval-
uate and compare the rheological implications of BRSs
versus metal stents over 3 years (15). This OCT- and
IVUS-based study will provide additional evidence of
the interaction ofﬂuidmechanicswith subsequent late
vascular response over the scaffolded segments and
the proximal and distal edges in straight or curved
geometries.
The second mechanistic question is why was the
lumen loss at the proximal edge numerically greater
compared with that at the distal edge at 3 years?
Although similar proximal edge vascular responses
have been reported after deployment of metal DES,
one might expect greater distal edge neointimal pro-
liferation with BRS due to the scaffold deployment in
a vessel that tapers distally causing potentially
step down regions responsible for hemodynamic
disturbances and subsequent greater edge responses
and a higher rate of distal versus proximal edge
healed dissections (42% vs. 24%, respectively). These
observations might inform the future manufacturing
of tapered tubes or hybrid scaffolds with more elastic
materials at the inﬂow areas or proximal segments
compared with the middle or outﬂow segments.
The third important angle of this observational
study has to do with the OCT evaluation of the edge
vascular response. Despite its limited penetration,OCT’s higher spatial resolution and faster pullback
speeds (20 to 40 mm/s for OCT vs. 0.5 mm/s for IVUS)
minimize the effect of longitudinal displacement of
the imaging transducer, allowing for sharper demar-
cation of the proximal and distal scaffold edges
compared with IVUS (Figure 1).
Some limitations of the current study should be
noted. First, this study was of limited size with a
dropout rate of almost 50%. In the setting of this
small ﬁnal sample size, the results of this study
should be considered as hypothesis generating. Sec-
ond, it should be clariﬁed that this assessment
included non-TLR cases excluding 2 proximal and 1
distal edge effects, which raised the rate of edge-
derived TLR in the complete ABSORB Cohort B trial
to 3%. Third, discrepancies in the rates of proximal
edge neointimal proliferation between the 2 cohorts
(B1 and B2) are not explicable by the data provided.
Data on degree of vascular curvature and angulation
of the treated coronary segments might explain the
varied stimulus for differential neointimal growth.
Finally, the majority of lesions treated were type B
(95%), with a maximal length of 14 mm (scaffold
length, 18 mm), and what the vascular response
would be in the setting of real-world PCI cannot be
predicted from this study. We hope to gain greater
insights into the effect of Absorb BVS in more com-
plex lesion subsets and subsequent in-segment
vascular responses from the ongoing randomized
RESTORATION study.
In vivo multimodality imaging after BRS im-
plantation has provided important insights into the
biological and mechanical properties of this novel
revolutionary technology. In-scaffold and edge
vascular response evaluated by light-based imaging
at 3 years demonstrate a favorable pattern of
tissue proliferation that does not signiﬁcantly differ
from that of conventional DES. However, after almost
a decade of intense clinical and translational re-
search within this space, the ongoing phase III and IV
clinical trials with intermediate-term outcomes are
designed to demonstrate noninferiority and not su-
periority of BRSs compared with third-generation
DES. The promised advantage of the BRS remains
the potential for long-term superior outcomes re-
sulting from gradual scaffold resorption and a more
favorable short- and long-term biomechanical and
vascular response.
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